Treatment for Sectoral (Non-Necrotizing Anterior) Scleritis
For sectoral non-necrotizing anterior scleritis, subconjunctival corticosteroid injection (triamcinolone 2-4 mg) is the recommended first-line treatment, providing rapid symptom relief within 1-2 weeks with an average symptom-free interval of 18 weeks and minimal risk of complications 1.
Treatment Algorithm
First-Line: Local Corticosteroid Therapy
Subconjunctival triamcinolone injection is highly effective for localized, non-necrotizing anterior scleritis:
- Efficacy: 90% of patients achieve symptomatic relief with clinically observable improvement in inflammation 1
- Onset: Symptoms typically resolve within 1-2 weeks, often by day 2 2, 3
- Duration: Average symptom-free interval of 18 weeks (approximately 4.5 months) 1, 3
- Dosing: 2-4 mg preservative-free triamcinolone acetonide injected subconjunctivally at the site of inflammation 3
- Technique: Can be performed under topical or peribulbar anesthesia at the slit lamp 2, 3
Safety profile is excellent: No cases of scleral thinning, perforation, or glaucoma in the largest case series 1. Complications are limited to transient subconjunctival hemorrhage (common but benign), transient ocular hypertension (rare), and potential cataract progression with repeated injections 3.
Alternative Local Option
Subconjunctival dexamethasone implant (0.7 mg Ozurdex) can be used if available, with the implant remaining visible for at least 45 days and providing sustained anti-inflammatory effect 2.
When to Escalate to Systemic Therapy
Consider systemic treatment if:
- Bilateral disease is present
- Recurrent disease requiring frequent local injections (>3-4 times per year)
- Inadequate response to local therapy within 2 weeks
- Associated systemic autoimmune disease is identified 4
Systemic Treatment Options (When Needed)
If local therapy fails or systemic treatment is indicated:
- Oral NSAIDs or corticosteroids as initial systemic therapy
- Steroid-sparing immunomodulatory agents if prolonged treatment needed:
- Biologic therapy reserved for refractory cases not controlled by conventional immunosuppression 4
Key Clinical Considerations
Monitor for these specific parameters post-injection:
- Pain relief and reduction in scleral congestion (primary endpoints)
- Intraocular pressure at each follow-up visit
- Scleral integrity (no thinning or necrosis)
- Cataract progression with repeated injections
Critical pitfall to avoid: Do not use subconjunctival corticosteroids in necrotizing scleritis, as this carries risk of scleral perforation. Sectoral non-necrotizing scleritis is specifically amenable to this approach because the inflammation is localized and the sclera is not thinned 1, 6.
Practical advantage: Local corticosteroid therapy allows 45% of patients to avoid any further systemic immunosuppressive therapy entirely 1, and enables reduction or discontinuation of systemic medications in those already on treatment 3.